Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Clinical trial NCT04443309 · UNKNOWN
Trial details
- NCT number
- NCT04443309
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-11
- Primary completion
- 2024-08-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.